345 related articles for article (PubMed ID: 28842494)
21. Kinetics of amyloid and prion fibril formation in the absence and presence of dense shell sugar-decorated dendrimers.
Ottaviani MF; Cangiotti M; Fiorani L; Fattori A; Wasiak T; Appelhans D; Klajnert B
Curr Med Chem; 2012; 19(34):5907-21. PubMed ID: 22834819
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Compound That Disrupts Binding of Amyloid-β to the Prion Protein Using a Novel Fluorescence-based Assay.
Risse E; Nicoll AJ; Taylor WA; Wright D; Badoni M; Yang X; Farrow MA; Collinge J
J Biol Chem; 2015 Jul; 290(27):17020-8. PubMed ID: 25995455
[TBL] [Abstract][Full Text] [Related]
23. Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures.
Bate C; Williams A
Neurobiol Dis; 2018 Mar; 111():48-58. PubMed ID: 29272738
[TBL] [Abstract][Full Text] [Related]
24. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.
Resenberger UK; Harmeier A; Woerner AC; Goodman JL; Müller V; Krishnan R; Vabulas RM; Kretzschmar HA; Lindquist S; Hartl FU; Multhaup G; Winklhofer KF; Tatzelt J
EMBO J; 2011 May; 30(10):2057-70. PubMed ID: 21441896
[TBL] [Abstract][Full Text] [Related]
25. Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic Aβ Oligomer Detection.
Tsukakoshi K; Kubo R; Ikebukuro K
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498917
[TBL] [Abstract][Full Text] [Related]
26. Preferential Recruitment of Conformationally Distinct Amyloid-β Oligomers by the Intrinsically Disordered Region of the Human Prion Protein.
Madhu P; Mukhopadhyay S
ACS Chem Neurosci; 2020 Jan; 11(1):86-98. PubMed ID: 31808343
[TBL] [Abstract][Full Text] [Related]
27. β-amyloid oligomers and prion protein: Fatal attraction?
Forloni G; Balducci C
Prion; 2011; 5(1):10-5. PubMed ID: 21150333
[TBL] [Abstract][Full Text] [Related]
28. Regulation of Amyloid β Oligomer Binding to Neurons and Neurotoxicity by the Prion Protein-mGluR5 Complex.
Beraldo FH; Ostapchenko VG; Caetano FA; Guimaraes AL; Ferretti GD; Daude N; Bertram L; Nogueira KO; Silva JL; Westaway D; Cashman NR; Martins VR; Prado VF; Prado MA
J Biol Chem; 2016 Oct; 291(42):21945-21955. PubMed ID: 27563063
[TBL] [Abstract][Full Text] [Related]
29. Soluble Aβ aggregates can inhibit prion propagation.
Sarell CJ; Quarterman E; Yip DC; Terry C; Nicoll AJ; Wadsworth JDF; Farrow MA; Walsh DM; Collinge J
Open Biol; 2017 Nov; 7(11):. PubMed ID: 29142106
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
[TBL] [Abstract][Full Text] [Related]
31. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
32. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
33. Evidence for aggregation-independent, PrP
Foley AR; Roseman GP; Chan K; Smart A; Finn TS; Yang K; Lokey RS; Millhauser GL; Raskatov JA
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28625-28631. PubMed ID: 33139554
[TBL] [Abstract][Full Text] [Related]
34. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism.
Cohen SI; Linse S; Luheshi LM; Hellstrand E; White DA; Rajah L; Otzen DE; Vendruscolo M; Dobson CM; Knowles TP
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9758-63. PubMed ID: 23703910
[TBL] [Abstract][Full Text] [Related]
35. Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.
Pagano K; Galante D; D'Arrigo C; Corsaro A; Nizzari M; Florio T; Molinari H; Tomaselli S; Ragona L
Mol Neurobiol; 2019 Mar; 56(3):1957-1971. PubMed ID: 29981054
[TBL] [Abstract][Full Text] [Related]
36. Engineering of a peptide probe for β-amyloid aggregates.
Aoraha E; Candreva J; Kim JR
Mol Biosyst; 2015 Aug; 11(8):2281-9. PubMed ID: 26073444
[TBL] [Abstract][Full Text] [Related]
37. Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.
Iraci N; Stincardini C; Barreca ML; Biasini E
Virus Res; 2015 Sep; 207():62-8. PubMed ID: 25456402
[TBL] [Abstract][Full Text] [Related]
38. Amyloidogenic properties of the prion protein fragment PrP(185-208): comparison with Alzheimer's peptide Abeta(1-28), influence of heparin and cell toxicity.
Cortijo-Arellano M; Ponce J; Durany N; Cladera J
Biochem Biophys Res Commun; 2008 Apr; 368(2):238-42. PubMed ID: 18206983
[TBL] [Abstract][Full Text] [Related]
39. Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
Haas LT; Strittmatter SM
J Biol Chem; 2016 Aug; 291(33):17112-21. PubMed ID: 27325698
[TBL] [Abstract][Full Text] [Related]
40. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
Jean L; Thomas B; Tahiri-Alaoui A; Shaw M; Vaux DJ
PLoS One; 2007 Jul; 2(7):e652. PubMed ID: 17653279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
